Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)

The purpose of this study is to determine the maximum tolerated dose of the chemotherapy drugs nab-paclitaxel and gemcitabine when combined with hypofractionated ablative proton therapy for the treatment of locally advanced pancreatic cancer. You will receive proton therapy once a day (Monday - Friday) for 3 weeks. Participants will also receive chemotherapy on each Monday of those three weeks.

Trial Details

NCT ID
NCT03652428
Phase
PHASE1 / PHASE2
Sponsor
University of Maryland, Baltimore
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Gemcitabine
  • Hypofractionated Ablative Proton Therapy
Locations (sample)
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Baltimore, Maryland, United States|39.29038,-76.61219

Key Eligibility Criteria

  • Cytologic or histologic proof of adenocarcinoma of the pancreas.
  • Nonmetastatic pancreatic cancer. Metastatic disease includes spread to distant (non-regional) lymph nodes, organs, peritoneum and ascites.
  • Unequivocal radiographic findings contraindicating resection including, but not limited to, solid tumor contact with any of the following: 1) the S…
  • ECOG Performance Status 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →